The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase
- 3 May 2004
- journal article
- research article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 491 (2-3), 93-99
- https://doi.org/10.1016/j.ejphar.2004.03.025
Abstract
Thymidine phosphorylase (platelet-derived-endothelial-cell-growth-factor) catalyzes the reversible phosphorolysis of thymidine to thymine and 2-deoxyribose-1-phosphate, activates 5'-deoxy-5-fluorouridine (5'DFUR) and inactivates trifluorothymidine (TFT). The effect of 5'DFUR and TFT with or without a specific thymidine phosphorylase inhibitor (TPI) on thymidine phosphorylase mRNA, protein expression and activity was studied, in three human colon cancer cell lines, WiDR, HT29 and Lovo exposed for 72 h at IC50 concentrations. In Lovo cells TFT plus TPI only increased thymidine phosphorylase-protein expression 1.7-fold; 5'DFUR and TFT treatment increased thymidine phosphorylase mRNA levels 5- and 1.4-fold, respectively. In WiDR cells, 5'DFUR plus TPI significantly decreased thymidine phosphorylase-protein. TFT and TFT plus TPI increased thymidine phosphorylase-protein 2- and 3-fold, respectively. TPI and 5'DFUR decreased thymidine phosphorylase-mRNA levels significantly. In HT29 cells, 5'DFUR and 5'DFUR plus TPI decreased both thymidine phosphorylase-protein and thymidine phosphorylase-mRNA. In all cell lines 5'DFUR and TFT did not affect thymidine phosphorylase activity, but treatment with TPI (alone or in combination) eliminated thymidine phosphorylase activity. This demonstrated that regulation is drug and cell line dependent.Keywords
This publication has 26 references indexed in Scilit:
- Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivityBritish Journal of Cancer, 2003
- Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy.Current Cancer Drug Targets, 2001
- Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alphaBritish Journal of Cancer, 2000
- Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosidesBiochemical Pharmacology, 2000
- Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5?-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsInternational Journal of Cancer, 1999
- Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugsDrug Resistance Updates, 1999
- Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylaseBritish Journal of Cancer, 1999
- Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMFAnnals Of Oncology, 1997
- Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridineCancer Chemotherapy and Pharmacology, 1993
- Angiogenic factorNature, 1992